Informing the pharmaceutical and biotech industry.
Industry Standard Research (ISR) today announced the availability of their latest report, “Hepatitis C: Social Media, Search, and Market Analysis,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and search analysis detailing how individuals discuss and search for Hepatitis C information, where they go to find it, and how their search progresses.
“Hepatitis C is the leading cause of liver cancer in the US and is believed to affect 170–200 million individuals worldwide” explained Andrew Schafer, President of ISR. “Given the ups and downs in recent weeks, expectations for Hep C treatments remain high. This report gives both clinical development and brand managers information they need to meet these expectations.”
ISR’s report includes a social media and search analysis of Hepatitis C.
“The analysis of natural search engine ranking pages (SERPs) of commonly searched keyword phrases in the Hep C search continuum uncovered a gap in what information users were searching for and what they expected to receive,” Schafer explained. “With few products available, this gap represents a tremendous opportunity for a drug maker to assert themselves as the information resource for Hepatitis C.”
ISR’s report also provides a disease overview; profile of current products and companies in the market; addressable market; and in-depth analysis of clinical trial activity, including 707 trials that are on-going or have been completed in the past two years to provide further understanding of Hepatitis C clinical development environment and trends. Analysis includes the number of trials by phase, the average enrollment, the average length of the studies, the sponsor type, and the types of studies being run.
The report profiles the products and pipelines of 10 companies, including Achillion, BMS, Boehringer Ingelheim, Genentech/Roche, Gilead Sciences, Idenix, Johnson & Johnson, Merck, Novartis, and Vertex.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.